Welcome to our dedicated page for Rezolute news (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.
Rezolute, Inc. (Nasdaq: RZLT) is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), including congenital and tumor forms of the condition. The RZLT news feed highlights company announcements, clinical trial updates, regulatory interactions and corporate developments related to its lead antibody therapy, ersodetug.
Investors and followers of Rezolute can use this page to review detailed updates on key Phase 3 programs such as the sunRIZE study in congenital hyperinsulinism and the upLIFT study in tumor hyperinsulinism. Company news has included topline results from sunRIZE, insights into pharmacologic activity and placebo effects in glucose endpoints, and plans to discuss the full dataset with the U.S. Food and Drug Administration under Breakthrough Therapy Designation.
News items also cover the evolution of the upLIFT trial design after alignment with the FDA on a streamlined, single-arm, open-label approach, as well as data from an Expanded Access Program in tumor HI that informed this strategy. In addition, Rezolute regularly reports on financial results, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), participation in healthcare and investor conferences, and leadership appointments that support its development and potential commercialization plans for ersodetug.
By following RZLT news, readers can track how Rezolute communicates progress in its clinical programs, interprets study findings, and engages with regulators and the investment community. This page provides a centralized view of the company’s press releases and related disclosures, offering context for the ongoing development of ersodetug in rare hyperinsulinism indications.
Rezolute, Inc. (Nasdaq: RZLT) has appointed Dr. Vlad Hogenhuis and Dr. Nerissa C. Kreher to its Board of Directors as the company advances its lead candidate, RZ358, through late-stage clinical trials for congenital hyperinsulinism.
Dr. Hogenhuis brings extensive experience in rare diseases and has held significant roles in global pharmaceutical companies. Dr. Kreher has a robust background in clinical development within the biotech sector. Their expertise is expected to enhance Rezolute's growth as it continues to develop therapies for rare metabolic disorders.
Rezolute, Inc. (Nasdaq: RZLT) announced CEO Nevan Charles Elam will present at two upcoming virtual investor conferences. The first is the Cowen 41st Annual Health Care Conference on March 3, 2021, at 4:00 p.m. ET. The second is the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 2:30 p.m. ET. Webcasts will be accessible on the conference portals. Rezolute is advancing therapies for rare diseases, focusing on RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. For details, visit their website.
Rezolute, Inc. (RZLT) reported a net loss of $7.1 million, or $0.88 per share, for Q2 FY2021, an increase from a loss of $6.7 million, or $1.14 per share, in Q2 FY2020. Cash and cash equivalents were $37.0 million as of December 31, 2020, bolstered by $37.5 million from an October 2020 financing round. The ongoing Phase 2b study of RZ358 for congenital hyperinsulinism is enrolling patients, with results expected in H2 2021. Additionally, Rezolute initiated a Phase 1 study of RZ402 in January 2021, targeting diabetic macular edema, with completion anticipated in H1 2021.
Rezolute (RZLT) has initiated dosing in a Phase 1 clinical trial for RZ402, an oral plasma kallikrein inhibitor targeting diabetic macular edema (DME). This trial (RZ402-101) aims to assess safety, tolerability, and pharmacokinetics in healthy adults, with completion expected in early 2021. This milestone expands Rezolute's pipeline, reinforcing its commitment to novel therapies for serious metabolic diseases. RZ402's oral administration could optimize treatment outcomes for DME, where current therapies face compliance challenges.
Rezolute, Inc. (Nasdaq:RZLT) announced the appointment of IssuerDirect as its new registrar, transfer agent, and shareholder support provider, replacing VStock Transfer, LLC. This transition requires no action from shareholders. Rezolute is focused on developing therapies for rare and metabolic diseases, with its lead asset, RZ358, in Phase 2b for treating congenital hyperinsulinism. Another pipeline drug, RZ402, is an oral plasma kallikrein inhibitor, set to enter clinical development for diabetic macular edema.
Rezolute, Inc. (Nasdaq:RZLT) announced the FDA's clearance of an Investigational New Drug (IND) application for RZ402, an orally available plasma kallikrein inhibitor aimed at treating diabetic macular edema (DME). A Phase 1 clinical study is expected to start in Q1 2021. RZ402 has demonstrated over 80% reduction in retinal inflammation and vascular leakage in preclinical rodent models, with a favorable safety profile. This drug aims to address current treatment limitations by providing an effective oral alternative for DME, enhancing patient compliance.
Rezolute, Inc. (Nasdaq:RZLT) will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 23 to December 3, 2020. CEO Nevan Charles Elam will lead the presentation, accessible through the conference's recording library. Additionally, Rezolute will conduct 1x1 meetings, available upon request. The company focuses on developing targeted therapies for rare and metabolic diseases, with its lead asset RZ358 in Phase 2b for congenital hyperinsulinism. RZ402 is also set to enter clinical trials for diabetic macular edema.
Rezolute, Inc. (OCTQB:RZLT) has announced a $41 million private placement financing led by CAM Capital, with participation from other notable investors. The funds will advance RZ358 for congenital hyperinsulinism, initiate a Phase 1 study for RZ402 targeting diabetic macular edema, and cover general corporate purposes, including a potential Nasdaq listing. The company plans to issue approximately 124 million shares at $0.33 each, accompanied by warrants. A reverse stock split of 1:50 is also anticipated to meet Nasdaq requirements.